Preclinical Ophthalmic Drug Development Services ace

Get in Touch ace

* First Name:
* Last Name:
* Business Email:
Phone:
Company/Institution:
Job Title:
* Services of Interest: Ocular Resolution Pharmacology and SPM Services
When do you expect your project to start?
Project Description:
* All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
* Tick to confirm the Research Use Only (RUO) statement.

Ocular Resolution Pharmacology and SPM Services

Resolution pharmacology offers a novel approach for ocular inflammatory diseases such as dry eye and uveitis. Ace Therapeutics provides tailored CRO services including SPM and resolvin quantification (LC-MS/MS), custom ocular inflammation models with pro-resolving endpoints, efferocytosis assays, and SPM receptor biomarker analysis for nonclinical research studies.

Understanding Ocular Resolution Pharmacology

Inflammation resolution is actively programmed by specialized pro-resolving mediators (SPMs). Among them, resolvins (e.g., Resolvin D1/E1) are particularly relevant to ocular pharmacology. In the eye, they act on corneal, uveal, and retinal tissues to limit neutrophil infiltration, enhance efferocytosis, reduce pro-inflammatory cytokines, promote M2-like macrophages, and protect against oxidative damage. These endogenous, self-limiting, and non-immunosuppressive actions make resolvins and other SPMs a promising therapeutic class for ocular surface and intraocular inflammatory diseases (e.g., dry eye, uveitis, diabetic retinopathy).

Fig. 1. Ocular resolution pharmacology and SPM services.

Our Ocular Resolution Pharmacology Service Portfolio

The following services are designed to support preclinical evaluation of SPM based and resolvin based candidates across key ophthalmic indications. Each offering can be customized to fit specific program needs.

Quantification of SPMs and Resolvins in Ocular Tissues

Technology: LC-MS/MS (triple quadrupole) with isotopic internal standards.
Sample types: Tear fluid, aqueous humor, vitreous, cornea, retina, choroid, and lacrimal gland.
Analytes: Resolvin D1-D6, Resolvin E1-E3, lipoxin A4/B4, protectin D1, maresin 1, and precursor fatty acids (EPA, DHA, AA).
Deliverables: Absolute concentrations (pg/mg tissue or pg/μL), temporal profiles, and comparison between disease vs. treatment groups.
Application: Assess endogenous SPM biosynthesis; confirm target engagement for candidates designed to stimulate resolution pathways.

Custom Ocular Inflammation Models with Pro-Resolving Endpoints

We have adapted standard models to include resolution-specific readouts:

Model	Species	Pro-Resolving Endpoints
Endotoxin-induced uveitis	Rat, Rabbit	Neutrophil clearance half-life (T50); M1/M2 macrophage ratio in iris/ciliary body
Chronic dry eye	Mouse	Corneal fluorescein clearance time; tear film SPM profile; goblet cell density
Corneal alkali burn	Rat	Re-epithelialization rate; neutrophil infiltration at 12/24/48h; corneal haze score
Laser-induced CNV with inflammation	Mouse	Inflammatory lesion area; F4/80+ cell colocalization with resolvin receptors
Experimental autoimmune uveitis	Mouse, Rat	Retinal structural recovery (OCT); Th17/Treg balance in draining lymph nodes

For each model, we can evaluate test articles (e.g., synthetic resolvin analogs, SPM-containing formulations, or drugs that upregulate endogenous SPM synthesis) alongside positive controls (dexamethasone, cyclosporine A) and vehicle.

Pharmacodynamic and Biomarker Assays

Efferocytosis assay: Phagocytosis of labeled apoptotic neutrophils by thioglycollate-elicited peritoneal or ocular macrophages (flow cytometry or fluorescence microscopy).
SPM receptor profiling: qPCR and IHC for GPR32, ALX/FPR2, ChemR23, GPR18, and GPR37 in ocular tissues.
Cytokine/chemokine panel: Multiplex for IL-1β, IL-6, TNF-α, IL-10, TGF-β, KC/GRO, MCP-1, and IL-17A.
Lipid mediator extraction & clean-up: Solid-phase extraction (SPE) optimized for small-volume ocular samples.
Enzyme activity assays: 5-LOX, 12-LOX, 15-LOX, and LTA4 hydrolase in corneal or retinal homogenates.

Customized Program Development for Resolution-Targeting Candidates

Mechanism validation: Determine if your compound actively resolves inflammation or simply suppresses pro-inflammatory signals (distinction critical for SPM mimetics).
Dose-ranging & formulation: Compatibility with topical drops, intravitreal injections, or sustained-release devices.
Comparative benchmarking: Head-to-head vs. standard-of-care (corticosteroids, NSAIDs, calcineurin inhibitors) on resolution indices.
Toxicology support: Histopathology with resolution-specific scoring (e.g., residual inflammatory cell aggregates vs. complete clearance).

Why Integrate Resolution Pharmacology Early in Development?

Traditional approach	Resolution-enhanced approach
Measures peak inflammation (e.g., 24h TNF-α)	Measures return to baseline (e.g., time to 50% neutrophil clearance)
Relies on anti-inflammatory efficacy (steroid-like)	Distinguishes pro-resolving vs. suppressive mechanisms
May miss candidates that work slowly but durably	Captures delayed but sustainable resolution
No SPM biomarker data	Provides mechanistic evidence for endogenous resolution engagement

Our team of ophthalmic pharmacologists and analytical chemists is ready to discuss your project. Whether you need a single assay (e.g., tear SPM profiling) or a full program from model selection to comprehensive study report, we provide transparent, scientifically rigorous services. contact us to request a quote or to schedule a technical consultation.

Frequently Asked Questions (FAQ)

What is the difference between anti-inflammatory and pro-resolving activity?

Anti-inflammatory agents (e.g., dexamethasone, NSAIDs) block pro-inflammatory mediator production or signaling but do not actively clear inflammatory cells or debris. Pro-resolving agents (e.g., resolvins, lipoxins) actively recruit non-phlogistic macrophages, enhance efferocytosis, and restore tissue homeostasis without full immune suppression. Our assays discriminate between these two mechanisms.

What controls do you recommend for a resolvin study?

We typically include: (a) vehicle control; (b) positive anti-inflammatory control (e.g., prednisolone acetate 1% for topical, or dexamethasone systemic); (c) a resolution-positive control (e.g., recombinant human Resolvin D1 or E1 if commercially available). We can also help source reference standards.

What sample volumes are required for SPM quantification from mouse tears?

A minimum of 3-5 µL of pooled mouse tear fluid is recommended for reliable LC-MS/MS detection of resolvins and other SPMs. For smaller volumes, we offer a high-sensitivity method with extended acquisition time. Please contact us to discuss your specific sample constraints.

Can you differentiate between endogenously produced SPMs and exogenously administered resolvins in the same sample?

Yes. Using stable isotope-labeled internal standards for each analyte, our LC-MS/MS method can distinguish native SPMs from deuterated or 13C-labeled test articles. This allows simultaneous quantification of baseline resolution mediator levels and pharmacokinetic assessment of exogenous resolvin analogs.

Do you offer ex vivo assays to confirm SPM receptor engagement in ocular tissues?

Yes. After in vivo treatment, we can isolate cornea, retina, or uveal tissue and perform receptor binding or downstream signaling assays (e.g., phosphorylation of ERK or CREB). Additionally, we provide receptor internalization assays using primary ocular macrophages or Müller cells.

How do your pro-resolving endpoints differ from standard anti-inflammatory readouts?

Standard anti-inflammatory endpoints (e.g., cytokine reduction or neutrophil count at a single early time point) do not capture resolution kinetics. Our pro-resolving endpoints include neutrophil clearance half-life (T50), efferocytosis index, M1/M2 macrophage ratio over time, and temporal lipid mediator profiling. These distinguish true resolution activity from general suppression.

Can you evaluate combination therapies involving a resolvin plus a conventional anti-inflammatory agent?

Absolutely. Many drug developers are interested in SPM-steroid or SPM-NSAID combinations for severe or chronic uveitis and post-surgical inflammation. Our models can assess additive or synergistic effects on resolution indices while monitoring potential interference with pro-resolving pathways (e.g., steroid inhibition of SPM biosynthesis).

For Research Use Only.